Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Press releases

May 23, 2022

Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states

Read press release
May 17, 2022

Immunovia, Inc. achieves Clinical Laboratory Licensure from Rhode Island Dept of Health making IMMray™ PanCan-d test available in 46 US states

Read press release
May 16, 2022

Immunovia strengthens its US team through the appointment of Natalie Carfora as Head of Market Access US

Read press release
April 28, 2022 | REGULATORY

Immunovia Publishes Interim Report January-March 2022

Read press release
April 21, 2022

Invitation to Immunovia’s Q1 presentation

Read press release
April 14, 2022 | REGULATORY

Immunovia CPT PLA Code submission for the IMMray™ PanCan-d test is on the agenda of American Medical Association

Read press release
April 7, 2022 | REGULATORY

Communiqué from the Annual General Meeting in Immunovia AB

Read press release
March 28, 2022 | REGULATORY

Immunovia appoints Jeff Borcherding, previously Chief Marketing Officer at Myriad Genetics, to lead Immunovia’s US business

Read press release
March 10, 2022 | REGULATORY

Immunovia publishes the annual report for 2021

Read press release
March 8, 2022

Immunovia, Inc. Laboratory Receives Accreditation from College of American Pathologists – a major step in the nationwide US roll-out of IMMray™ PanCan-d

Read press release
March 7, 2022

Immunovia further strengthens IP portfolio for its IMMray™ PanCan-d signature

Read press release
March 4, 2022 | REGULATORY

Notice to the Annual General Meeting of Immunovia AB (publ)

Read press release
1 4 5 6 7 8 27